1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
Delayed Nasdaq  -  04:00 2022-08-08 pm EDT
13.92 USD   +1.16%
07/27BioNTech, Pfizer Challenge CureVac's COVID-19 Vaccine Patent Infringement Case In US
MT
07/26BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims
RE
07/06MARKETSCREENER'S WORLD PRESS REVIEW : July 6, 2022
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CureVac Sues BioNTech for Alleged Infringement of Some COVID-19 Vaccine Patents

07/05/2022 | 08:03am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -7.54% 169.3 Delayed Quote.-28.97%
CUREVAC N.V. 1.16% 13.92 Delayed Quote.-59.43%
PFIZER, INC. 0.61% 49.57 Delayed Quote.-16.56%
All news about CUREVAC N.V.
07/27BioNTech, Pfizer Challenge CureVac's COVID-19 Vaccine Patent Infringement Case In US
MT
07/26BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims
RE
07/06MARKETSCREENER'S WORLD PRESS REVIEW : July 6, 2022
MS
07/05CUREVAC N : Files Patent Infringement Lawsuit in Germany Against BioNTech - Form 6-K
PU
07/05BioNTech Says Will 'Vigorously' Defend Patent Infringement Allegations
MT
07/05BioNTech Says 'Work is Original' Amid CureVac Lawsuit On mRNA-Related Patents Infringem..
MT
07/05SECTOR UPDATE : Health Care Stocks Decline Premarket Tuesday
MT
07/05CureVac Sues BioNTech in Germany for Infringement of mRNA-Related Patents
MT
07/05CureVac Sues BioNTech for Alleged Infringement of Some COVID-19 Vaccine Patents
MT
07/05CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
EQ
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Financials
Sales 2022 80,4 M 82,1 M 82,1 M
Net income 2022 -199 M -203 M -203 M
Net cash 2022 507 M 518 M 518 M
P/E ratio 2022 -12,7x
Yield 2022 -
Capitalization 2 547 M 2 603 M 2 603 M
EV / Sales 2022 25,4x
EV / Sales 2023 15,5x
Nbr of Employees 824
Free-Float 47,5%
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 13,62 €
Average target price 25,31 €
Spread / Average Target 85,9%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean Stéphenne Chairman-Supervisory Board
Igor Splawski Chief Scientific Officer
Malte Greune Chief Operating & Production Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-59.43%2 603
MODERNA, INC.-26.44%71 566
LONZA GROUP AG-26.08%43 806
IQVIA HOLDINGS INC.-16.80%43 579
SEAGEN INC.13.72%32 890
ALNYLAM PHARMACEUTICALS, INC.28.89%27 695